C

Codex DNA Inc
NASDAQ:DNAY

Watchlist Manager
Codex DNA Inc
NASDAQ:DNAY
Watchlist
Price: 2 USD 8.11% Market Closed
Updated: May 22, 2024

Net Margin
Codex DNA Inc

-176.7%
Current
-267.8%
Average
0.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-176.7%
=
Net Income
-48.5m
/
Revenue
27.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Codex DNA Inc
NASDAQ:DNAY
59.8m USD
-177%
US
Thermo Fisher Scientific Inc
NYSE:TMO
225.3B USD
14%
US
Danaher Corp
NYSE:DHR
197.4B USD
18%
US
Agilent Technologies Inc
NYSE:A
45B USD
18%
US
IQVIA Holdings Inc
NYSE:IQV
41.6B USD
9%
KR
Samsung Biologics Co Ltd
KRX:207940
55.4T KRW
23%
CH
Lonza Group AG
SIX:LONN
36.6B CHF
10%
US
Mettler-Toledo International Inc
NYSE:MTD
32.5B USD
21%
IE
ICON PLC
NASDAQ:ICLR
26.3B USD
8%
US
West Pharmaceutical Services Inc
NYSE:WST
24.6B USD
19%
US
Waters Corp
NYSE:WAT
20.9B USD
21%
C
Codex DNA Inc
NASDAQ:DNAY
Country US
Market Cap 59.8m USD
Net Margin
-177%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 225.3B USD
Net Margin
14%
Danaher Corp
NYSE:DHR
Country US
Market Cap 197.4B USD
Net Margin
18%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 45B USD
Net Margin
18%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 41.6B USD
Net Margin
9%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 55.4T KRW
Net Margin
23%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 36.6B CHF
Net Margin
10%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 32.5B USD
Net Margin
21%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 26.3B USD
Net Margin
8%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 24.6B USD
Net Margin
19%
Waters Corp
NYSE:WAT
Country US
Market Cap 20.9B USD
Net Margin
21%

Profitability Report

View the profitability report to see the full profitability analysis for Codex DNA Inc.

Full Profitability Report

See Also

Summary
DNAY intrinsic value, competitors valuation, and company profile.
DCF Valuation
DNAY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DNAY stock valuation using valuation multiples.
Wall Street Estimates
DNAY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DNAY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-176.7%
=
Net Income
-48.5m
/
Revenue
27.4m
What is the Net Margin of Codex DNA Inc?

Based on Codex DNA Inc's most recent financial statements, the company has Net Margin of -176.7%.

ALPHA SPREAD
Join more than 139,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.